Actively Recruiting
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
Led by Praxis Precision Medicines · Updated on 2025-08-21
60
Participants Needed
3
Research Sites
228 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
CONDITIONS
Official Title
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Seizure onset before 3 months of age
- Minimum weight of at least 10 kg at screening
- Documented SCN2A genetic variant confirmed by accredited genetic testing
- Additional inclusion criteria will be assessed by the study team
You will not qualify if you...
- Presence of other significant or pathogenic genetic variants besides SCN2A that may affect epilepsy or development
- Use of more than 2 sodium channel blocking anti-seizure medications
- Additional exclusion criteria will be assessed by the study team
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Le Bonheur Childrens Hospital
Memphis, Tennessee, United States, 38103
Completed
2
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035-003
Actively Recruiting
3
Praxis Research Site
São Paulo, Brazil, 05403-010
Actively Recruiting
Research Team
H
Head of Pharmacovigilance
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here